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Background: The clinical course of peritoneal and parietal recurrence of hepatocellular carcinoma (HCC-PPL) is not
well known.
Methods: Twenty-eight patients with a histologically proven HCC-PPL were analyzed out of a series of 515 patients
operated for HCC (group 1). The risk factors, histological features, growing dynamic and results of surgical treatment
were analyzed and compared with patients having other extrahepatic localizations of HCC (group 2; 26 patients).
Survival data were also compared with patients with intrahepatic-only recurrence (group 3; 211 patients).
Results: In group 1, a needle tract injury was present in 57.1% and a previous spontaneous rupture in 14.3% of cases.
Parietal seeding was generally single, while peritoneal seeding was frequently multiple. Grading was poor in 84.7%,
microvascular infiltration was observed in 57.1% and a rapid growth in 55.5% of cases. In Group 2, only 4 out of 26
patients underwent surgery. Survival was significantly better in group 3 than in group 1, and in group 1 than in group 2.
Conclusions: Extrahepatic HCC recurrence is related to an aggressive biology of the cancer; many characteristics of high
malignancy are usually present in these cases. After radical surgery for HCC-PPL, an acceptable survival may be obtained.
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In patients with hepatocellular carcinoma (HCC), extrahe-
patic recurrences are generally considered as an expression
of an advanced cancer not suitable for surgery [1-3].
Among these localizations, the growth of cancer in the
abdominal or thoracic wall and in the peritoneal cavity
is often regarded as the result of a neoplastic seeding,
induced by the passive transportation of tumor cells out
of the liver [4]. Some kind of “violation” of HCC integrity
is often demonstrated in these cases and interpreted as a
possible pathogenetic event. A percutaneous procedure
(needle tract injury), including needle biopsy (PB), ethanol
injection (PEI) or radiofrequency ablation (RFA), is
generally recorded [5]. Some cases are reported also after
transarterial chemoembolization and after surgery, as a
consequence of necrosis and intraoperative manipulation,
respectively. Finally, a spontaneous rupture of HCC may* Correspondence: baiocchi@med.unibs.it
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unless otherwise stated.produce a spillage of tumor cells in the peritoneal surface
[6,7] with possible seeding and multiple nodule growth.
It is not clear if the parietal and/or peritoneal localiza-
tions of HCC (HCC-PPL) present the same biologic and
prognostic value as other extrahepatic metastases - simply
representing the growth of viable cells outside the liver - or,
on the contrary, if they are related to a particular biologic
aggressiveness of the neoplasm. Literature is very scarce in
this field [6,8,9]; in the published studies, HCC-PPL is
generally considered together with other extrahepatic
localizations [10,11]. Furthermore, the largest surveys and
few multicentric reviews available are oriented toward the
risk of seeding after the different percutaneous procedures
rather than toward the descriptions of the natural history
of these patients [12-14].
In this study, we report a series of patients with HCC-
PPL and discuss the pathogenesis, clinical manifestation,
treatment and survival in the light of our 20 years experi-
ence of more than 500 patients submitted to liver resection
for HCC.al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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This retrospective study includes, out of 515 HCC
patients operated in the period 1990 to 2011 in the
Surgical Clinic of the University of Brescia, 28 patients
with HCC-PPL (group 1), 26 patients with extrahepatic
recurrence of HCC not located in the thoracic and
abdominal wall nor in the peritoneum (group 2) and, only
for survival analysis, 211 patients with intrahepatic-limited
recurrence (group 3). Recurrences were always diagnosed
by computed tomography (CT) or magnetic resonance
imaging; PB of the recurrence was performed in selected
cases. A needle tract injury was considered as the
causative event of PPL if there was an exact corres-
pondence of the parietal seeding with the trajectory of
the needle. Delay of appearance was noted, together
with the pathological features (location, size, number,
presence of a capsule, microvascular infiltration, invasion
of the surrounding tissue) both for the primary HCC
and of HCC-PPL. The rate of growth of HCC-PPL was
assessed by comparing CT to the final size on the
pathology report. Surgical resection was attempted in
every patient with an extrahepatic disease, provided
that the surgical risk was acceptable and that a radical
resection could be attempted, with the exception of bone
metastases which were treated with radiotherapy. Time
and type of a further recurrence, the need of an iterative
surgery and the reason for death were also recorded.
Overall survival, both from the treatment of the primary
tumor and from the treatment of recurrence, was deter-
mined and compared between the three groups.
Statistical analysis
The variables were scheduled as discrete or continuous,
and comparison was performed by means of the χ2 test
and the Student t test, respectively. Survival rates were
calculated using the Kaplan-Meier method; comparison
between the curves was performed by means of the Cox
proportional hazards model. P values less than 0.05 were
considered statistically significant.
Results
Study group
Cancer recurrence was diagnosed in 260 out of 515
patients resected for HCC (50.5%); in the majority of
cases (211 patients), the recurrence was only intrahepatic.
The remaining 49 patients showed an extrahepatic recur-
rence (multiple localizations in 34 cases). In 28 patients
(5.4%), the extrahepatic recurrence involved the thoracic
or the abdominal wall (13 patients) and/or the peritoneum
(17 patients). Two patients had both parietal and periton-
eal recurrence. In 26 cases an extrahepatic recurrence not
involving parietal wall and peritoneum was observed
(group 2). Study groups are summarized in Figure 1. In
both groups 1 and 2, in more than half of cases theextrahepatic recurrence was associated with a synchron-
ous liver recurrence.
Pathogenesis, clinical and pathological data
Clinical and pathological data are shown in Table 1. In
group 1, the primary HCC was exophitic in 39.3% of
cases, and the mean size was 6.2 cm (range 1 to 25 cm).
A needle tract injury was present in 15 patients (53.6%),
10 patients being submitted to a PB before surgery and
the other five patients being treated with PEI or RFA as a
primary therapy. Another four patients developed periton-
eal localizations after resection of ruptured HCC and one
patient after transarterial chemoembolization. Thus, eight
patients (28.6%) showed an HCC-PPL without iatrogenic
or spontaneous tumor rupture. Primary HCC of group 2
patients was similar in localization, while no previous PB
nor PEI/RFA were recorded in group 2.
Seeding was single in 15 patients and multiple in 13
patients (range 2 to 20 nodules) in group 1; the relative
incidence of single seeding varied according to the
localization of HCC implantation (100% for parietal
localization and 11.7% for peritoneal site; P < 0.001) and
the causative mechanism (50% after needle injury and
0% after HCC rupture; P = 0.07). On the contrary, extrahe-
patic recurrence was always multiple in group 2.
HCC-PPL appeared with a delay of 20 months on aver-
age, while non-PPL recurrence appeared with a 13-month
delay (P = not significant); the delay of PPL implantation
was different according to the causative mechanisms
(24 months after needle tract injury, 8 months after
spontaneous or iatrogenic HCC rupture, and 26 months
when no clear causative mechanism was present). Delay
was 15 months on average (range 4 to 23) in the five
patients primarily treated with PEI/RFA. The diagnosis
of metachronous HCC-PPL was made at first by clinical
evaluation (seven cases of parietal seeding) or CT during
follow-up. At CT, the lesions appeared as nodules in the
parietal wall or in the peritoneal cavity without ascites or
peritoneal thickening.
Treatment of patients presenting with parietal and/or
peritoneal localizations of hepatocellular carcinoma or
other extrahepatic recurrences
All 28 HCC-PPL patients were classified as “Child A”
(Child-Pugh Score). Surgery was attempted for all cases
and carried out in all but one (presenting multiple periton-
eal and hepatic recurrences; after open biopsy, this patient
was treated with supportive care and died in 1 month).
For the treatment of parietal localization of HCC (13
patients), simple excision of the nodule was performed
in two patients and en bloc resection of the abdominal/
thoracic wall in 11 patients (two of these patients needed
resection of the thoracic wall with the removal of the
rib and a reconstructive plastic surgery. For peritoneal
Figure 1 Flow chart of patient’s selection. PPL, parietal and/or peritoneal localization; pts, patients.
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cases and extended to the bowel, the stomach and the
liver for a direct infiltration in the other six; one patient
with peritoneal seeding of more than 20 nodules after
laparoscopic RFA of a small HCC required the resection
of the right kidney, the transverse colon and the small
bowel (Table 2). The synchronous liver recurrence was
treated in 15 patients by liver resection and in one patient
by PEI. Mean postoperative complications were pleuricTable 1 Clinical and pathological data of group 1 and group
Parameter
Primary HCC Site Exop
Subc
Deep
Primary treatment Rese
PEI/R
Tumor violation Need
Spon
TACE
No v
Number of PPL/extrahepatic lesions Singl
Multi
Intrahepatic-associated recurrences
Delay of appearance of recurrence
after the primary treatment (months)
After resection Mean
Rang
After PB/PEI/RFA Mean
Rang
HCC, hepatocellular carcinoma; PB, percutaneous biopsy; PEI, percutaneous ethanol
ablation; TACE, transarterial chemoembolization.effusion (11.1%), ascites (11.1%), and anemia (3.7%) as
summarized in Table 2. Mortality was nil; mean hospital
stay was 8 days.
In the 26 patients with extrahepatic recurrences without
HCC-PPL, surgery was feasible only in four cases (15.4%),
including a solitary metastasis in the lung, adrenal gland,
rib and lymph node at the hepatic pedicle. In five further
patients, bone metastases were treated with radiotherapy;
one patient received treatment with Sorafenib.2 patients
Group 1 (n = 28) Group 2 (n = 26)
hitic 39.3% 30.8%
apsular 7.1% 11.5%
53.6% 57.7%
ction 82.1% 100%
FA 17.9% 0%
le tract injury 53.6% 7.7
taneous HCC rupture 14.3% 0%
3.6% 0%
iolation 28.6% 92.3%
e 53.6% 0%
ple 46.4% 100%
60.7% 53.8%
20 13
e 1-45 2-44
15 –
e 4-23 –
injection; PPL, parietal and/or peritoneal localization; RFA, radiofrequency
Table 2 Surgical procedures and postoperative
complications of group 1
Treatment of parietal localization
of hepatocellular carcinoma
Number
of patients
Postoperative
complications
Simple excision of the nodule 2 –
En bloc resection 11 2 pleural effusion,
1 ascites
Resection limited to the
peritoneal nodules
7 1 ascites
Resection extended to
bowel, stomach and liver
6 1 pleural effusion,
1 ascites
Resection of kidney, transverse
colon and small bowel
1 1 anemia
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In group 1, 83 lesions were completely removed (free
surgical margin in all cases) including 30 nodules missed
at CT in six patients. The size was 4.8 cm on average
(range 1 to –22 cm), being larger than the primary HCC
in five cases. A significant increase (>25% in size) was
noted in five out of nine patients operated on 1 month
after CT. Grading was G1 in four cases and G2-G3
in 24 cases; all the multiple lesions showed the same
differentiation. In six patients, grading was poorer
than the primary HCC. Microvascular infiltration was
noted in 16 cases. The lesion infiltrated the surrounding
tissue in 3 out of 13 parietal and 8 out of 15 periton-
eal localizations. All eight patients without needle
tract injury or HCC rupture presented in the primary
HCC a poor grading and a capsule infiltration histo-
logically proven. Primary HCC was beyond Milan criteria
in seven out of these eight patients; two patients had
lymph node metastases at the time of primary surgery
(Table 3).
Compared with group 1, group 2 patients had a signifi-
cantly larger lesion (medium size 8.1 cm, range 1.5 to 16;Table 3 Macroscopic and histological data extrahepatic recur
Tumor characteristics
Size ≤3 cm
>3 cm
Mean (range) (cm)
Grading G1
G2-G3
G > primary HCC (n)
Capsule Yes
No
Vascular infiltration Yes
No
Infiltration of the surrounding organs Yes
No
Group 1, parietal and/or peritoneal localizations of hepatocellular carcinoma (HCC);P < 0.001) and a more frequent infiltration of the
surrounding organs (P < 0.031) (Table 3).
Survival data
At the time of writing, 10 patients out of 28 (group 1)
are living; death was due to liver failure in four patients
and to cancer progression in 14 patients. Survival rates
after surgery for recurrence were 66.7%, 44.4%, 37.0%
and 37.0% at 1, 2, 3 and 5 years, respectively, with a
mean survival of 16.1 months (Figure 2). Respective
survival rates were 72.7%, 54.5%, 45.5% and 45.5% in the
11 patients with only HCC-PPL recurrence, and 62.5%,
37.5%, 31.3% and 31.3% in the 17 patients who presented
associated hepatic recurrence (P = 0.21). Survival was
slightly poorer in the group of 20 patients resected after
iatrogenic or spontaneous HCC rupture than in the
eight patients without cancer violation (5 year survival
rates of 36.8% and 50.0%, respectively). Moreover, the
small subgroup of patients having had a tumor rupture
showed the worse results: a very low mean recurrence
timing (8 versus 20 months) and a bad overall survival
(15.3 versus 36 months from the primary treatment).
Starting from the time of the treatment of the primary
HCC, survival rates were 88.5%, 66.7%, 55.5% and 40.7%
at 1, 2, 3 and 5 years, significantly better than group 2
patients (58.3%, 33.3%, 29.2% and 20.8%; P = 0.002), and
significantly worse than group 3 patients (95.4%, 84.3%,
70.9%, 58.2%) (Figure 3). In group 2, survival after surgery
(mean 15 months) was better than survival with other
therapies (10 months) (P = 0.07) and comparable to the
patients with HCC-PPL treated by surgery.
As a whole, seven patients suffered a further HCC-PPL
recurrence. No local recurrence was observed after resec-
tion of a parietal seeding; in one patient, after the removal
of a 2-cm thoracic wall seeding after PB of a lung metasta-
sis, a further resection of a 1.5 cm seeding at the abdominalrence of HCC
Group 1 (n = 28) Group 2 (n = 26) P
60.7% 11.5 <0,001
39.3% 88.5
4.8 (1-22) 8.1 (1.5-16)
10.7% 30.8 0.15
89.3% 69.2
6 2
28.6% 34.6% 0.63
71.4% 65.4%
53.6% 76.9% 0.12
46.4% 23.1%
39.3% 65.4% <0.031
60.7% 34.6%
Group 2, extrahepatic non-parietal and/or peritoneal recurrences.
Figure 2 Overall survival in 27 patients treated with surgery for parietal and/or peritoneal localization recurrences of hepatocellular
carcinoma from the treatment of recurrence.
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for a peritoneal localization, a recurrence in the abdominal
cavity was observed in six patients (mean delay 9 months),
treated by surgery in three cases.Discussion
Our experience, the largest from a western country,
suggests that HCC-PPL is rare. The main pathogenetic
mechanism seems to be related to the preoperative viola-
tion of the cancer integrity rather than to an intraoperative
dissemination; a needle tract injury or a spontaneous
rupture of the tumor was documented in 71.4% of our
cases. This hypothesis is easy to demonstrate in the
parietal localization with the exact coincidence of the
lesion with the trajectory of the needle, while it is not
proven that percutaneous procedures or HCC ruptureFigure 3 Overall survival of patients with parietal and/or peritoneal loc
patients with non-PPL extrahepatic metastases (Group 2) and patients w
primary hepatocarcinoma.carry a significant increase of the risk of peritoneal
localization as well [5].
Yeh and Chen observed that the rate of a spontaneous
rupture was comparable between patients with peri-
toneal localization and patients who never recurred
(25.5% and 16.4%) [8]. Kwak and colleagues, comparing
the patients with peritoneal localization to a randomly
matched control group, noted the same rate of needle
tract injury (30.9% and 26.5%) while HCC rupture (19.1%
and 4.4%) was confirmed as an independent risk factor
(P = 0.008) [5]. These studies stated that a peritoneal
recurrence does not necessarily appear in every patient
after a spontaneous rupture of HCC, as in our experience
too, but were unable to define the pathogenetic role of
the percutaneous procedures. In an extensive literature
review, including no series presenting more than 15
cases, Stigliano and colleagues summarized a medianalization (PPL) recurrences of hepatocellular carcinoma (Group 1),
ith intrahepatic-only recurrence (Group 3) after treatment of
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the lowest risk being reported for RFA (0.61%) [14];
however, a higher incidence, up to 5.1%, has been recently
reported [13,15].
The rate of growth of these lesions, accurately repre-
sented by CT [12,16], can be particularly quick, as in
55.5% of our patients, leading to a recurrent cancer larger
than the primary one in spite of the periodic controls. The
analysis of the specimens showed a G2-G3 differentiation
in the majority of our patients (86.6%), grading being
poorer than the primary tumor in six patients. Both these
data support the hypothesis that seeding could reflect a
particular aggressiveness of the cancer. This fact could
explain the relatively unsatisfactory results obtained by
apparently radical treatments [13]. Thus, the growth of a
mass in the peritoneum could be really considered as an
extrahepatic metastasis; the biologic features of primary
HCC in these cases were unfavorable with poor grading
and infiltration of the tumor capsule.
Nonetheless, unlike the other types of peritoneal car-
cinomatosis, the peritoneal localization of HCC is the
reason of death only in a limited number of patients
[17]; the lesion is generally suitable for curative resection
for the nodular aspect of the recurrence without “carcin-
omatosis peritonei” [6,16]. Some patients can require an
extension of resection to the nearest organs, as in 56%
of our patients.
On the whole, the prognosis for these patients is not
satisfactory. Our experience presents less favorable results
than Ding and colleagues (2-year’s survival of 71% in a
collective review of 24 patients) [18]. Nonetheless, also
from this experience, survival is clearly better than for
the other extrahepatic recurrences, which are submitted
to a curative procedure only in a minority of cases. So,
for HCC-PPL, treatment must always be considered in
patients are fit for surgery, provided that other localiza-
tions are absent or suitable for radical care. At surgery,
the entire abdominal space must be explored, as many
small seedings could be undetected before surgery; a
further peritoneal recurrence is not rare (50% in our
experience), and is suitable for a further resection in
selected cases [18,19]. On the contrary, surgery for
parietal localization usually does not involve the risk of
further local recurrence provided that a wide en bloc
resection of the wall is performed, extended to the
surrounding organs if required [20-22].
The different mechanisms of the seeding between the
peritoneal localization (violation of the tumor in open
space) and the wall localization (transport of viable
cells along the narrow needle trajectory) may explain
the different risk of failure, even if a negative surgical
margin was obtained. An aggressive attitude is justified
in the peritoneal localizations resulting from seeding
after spontaneous rupture of HCC as well; long-termresults are acceptable, particularly considering the negative
factors of these cancers at presentation.
Moreover, at this time there is no evidence in the
literature for different therapies (such as radiotherapy
or drugs such as Sorafenib) that could treat this kind of
recurrence.
Conclusion
HCC-PPL can be interpreted as a marker of an aggressive
biology of the cancer. A radical treatment rarely means
long-term survival but offers definitively better results
than abstention from treatment. The better survival com-
pared to the other extrahepatic localizations seems to
be related to a favorable presentation, more frequently
suitable for a surgical resection, rather than a different
biologic behavior. Even if this study has the problems
of a long study period, is retrospective in nature and has a
small sample size, our results justify surgery in selected
patients when a radical purpose is pursued in the general
context of the HCC diffusion.
Abbreviations
CT: computed tomography; HCC: hepatocellular carcinoma; HCC-PPL: parietal
and/or peritoneal localizations of HCC; PB: percutaneous biopsy;
PEI: percutaneous ethanol injection; RFA: radiofrequency ablation.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
Study concept and design: NP; acquisition of data: SM, DL; helped supervise
the field activities: GLB, FG; analysis and interpretation of data: NP, SM;
drafting of the manuscript: NP; study supervision: SMG. All authors read and
approved the final manuscript.
Received: 5 September 2013 Accepted: 9 May 2014
Published: 25 September 2014
References
1. Uka K, Aikata H, Takaki S, Shirakawa H: Clinical features and prognosis of
patients with extrahepatic metastases from hepatocellular carcinoma.
World J Gastroenterol 2007, 13:414–420.
2. Yang Y, Nagano H, Ota H, Morimoto O, Nakamura M, Wada H, Noda T,
Damdinsuren B, Marubashi S, Miyamoto A, Takeda Y, Dono K, Umeshita K,
Nakamori S, Wakasa K, Sakon M, Monden M: Patterns and
clinicopathologic features of extrahepatic recurrence of hepatocellular
carcinoma after curative resection. Surgery 2007, 141:196–202.
3. Llovet JM, Bru C, Bruix J: Prognosis of hepatocellular carcinoma: the BCLC
staging classification. Semin Liver Dis 1999, 19:329–338.
4. Sakurai M, Okamura J, Seki K, Kuroda C: Needle tract implantation of
hepatocellular carcinoma after percutaneous liver biopsy. Am J Surg Pathol
1983, 7:191–195.
5. Kwak MS, Lee JH, Yoon JH, Yu SJ: Risk factors, clinical features, and
prognosis of the hepatocellular carcinoma with peritoneal metastasis.
Dig Dis Sci 2012, 57:813–819.
6. Kiroyuki H, Saito S, Yoneda M, Fujita K, Mawatari H, Uchiyama T, Higurashi T,
Imajo K, Sakaguchi T, Atsukawa K, Sawabe A, Kanesaki A, Takahashi H, Abe Y,
Inamori M, Kobayashi N, Kubota K, Ueno N, Nakajima A: Outcome and factors
influencing survival in cirrhotic cases with spontaneous rupture of
heptocellular carcinoma: a multicentric study. BMC Gastroenterol 2009, 9:29.
7. Sonoda T, Kanematsu T, Takenaka K, Sugimachi K: Ruptured hepatocellular
carcinoma evokes risk of implanted metastases. J Surg Oncol 1989,
41:183–186.
Portolani et al. World Journal of Surgical Oncology 2014, 12:298 Page 7 of 7
http://www.wjso.com/content/12/1/2988. Yeh CN, Chen MF: Resection of peritoneal implantation of hepatocellular
carcinoma after hepatic resection: risk factors and prognostic analysis.
World J Surg 2004, 28:382–386.
9. Lin CC, Liang HP, Lee HS, Huang GT, Yang PM, Ho MC, Lee PH, Tsang YM,
Chen DS, Sheu JC, Chen CH: Clinical manifestation and survival of hepatocellular
carcinoma patients with peritoneal metastasis. J Gastroenterol Hepatol 2009,
24:815–820.
10. Taketomi A, Toshima T, Kitagawa D, Motomura T, Takeishi K, Mano Y,
Kayashima H, Sugimachi K, Aishima S, Yamashita Y, Ikegami T, Gion T,
Uchiyama H, Soejima Y, Maeda T, Shirabe K, Maehara Y: Predictors of
extrahepatic recurrence after curative hepatectomy for hepatocellular
carcinoma. Ann Surg Oncol 2010, 17:2470–2476.
11. Tanaka K, Shimada H, Matsuo K, Takeda K, Nagano Y, Togo S: Clinical
features of hepatocellular carcinoma developing extrahepatic
recurrences after curative resection. World J Surg 2008, 32:1738–1747.
12. Chang S, Kim SH, Lim HK, Kim SH, Lee WJ, Choi D, Kim YS, Rhim H: Needle
tract implantation after percutaneous interventional procedures in
hepatocellular carcinomas: lessons learned from a 10-years experience.
Korean J Radiol 2008, 9:268–274.
13. Shirai K, Tamai H, Shingaki N, Mori Y, Moribata K, Enomoto S, Deguchi H,
Ueda K, Maekita T, Inoue I, Iguchi M, Yanaoka K, Oka M, Ichinose M: Clinical
features and risk factors of extrahepatic seeding after percutaneous
radiofrequency ablation for hepatocellular carcinoma. Hepatol Res 2011,
41:738–745.
14. Stigliano R, Marelli L, Yu D, Davies N, Patch D, Burroughs AK: Seeding
following percutaneous diagnostic and therapeutic approaches for
hepatocellular carcinoma. What is the risk and the outcome? Seeding risk
for percutaneous approach of HCC. Cancer Treat Rev 2007, 33:437–447.
15. Imamura J, Tateishi R, Shiina S, Goto E, Sato T, Ohki T, Masuzaki R, Goto T,
Yoshida H, Kanai F, Hamamura K, Obi S, Yoshida H, Omata M: Neoplastic
seeding after radiofrequency ablation for hepatocellular carcinoma.
Am J Gastroenterol 2008, 103:3057–3062.
16. Kim TK, Han JK, Ching JW, Choi BI, Park JH, Han MC: Intraperitoneal drop
metastases from hepatocellular carcinoma: CT and angiographic
findings. J Comp Assist Tom 1996, 20:638–642.
17. Matsukuma S, Sato K: Peritoneal seeding of hepatocellular carcinoma:
clinicopathological characteristics of 17 autopsy cases. Pathol Int 2011,
61:356–362.
18. Ding JH, Chua TC, Al-Mohaimeed K, Moris DL: Hepatocellular carcinoma
peritoneal metastases: report of three cases and collective review of the
literature. Ann Acad Med Singapore 2010, 39:734–737.
19. Takahashi H, Konishi M, Nakagohri T, Inoue K, Takahashi S, Tanizawa Y,
Monden M, Kinoshita T: Aggressive multimodal treatment for peritoneal
dissemination and needle tract implantation for hepatocellular
carcinoma: a case report. Jpn J Clin Oncol 2004, 34:551–553.
20. Durand F, Regimbeau JM, Belghiti J, Sauvanet A, Vilgrain V, Terris B,
Moutardier V, Farges O, Valla D: Assessment of the benefit and the risks of
percutaneous biopsy before surgical resection of hepatocellular
carcinoma. J Hepatol 2001, 35:254–258.
21. Ahn DW, Shim JH, Yoon JH, Kim CY, Lee HS, Kim YT, Kim YJ: Treatment and
clinical outcome of needle-track seeding from hepatocellular carcinoma.
Korean J Hepatol 2011, 17:106–112.
22. Portolani N, Baiocchi GL, Coniglio A, Grazioli L, Frassi E, Gheza F, Giulini SM:
Sequential multidisciplinary treatment of hepatocellular carcinoma: the
role of surgery as rescue therapy for failure of percutaneous ablation
therapies. J Surg Oncol 2009, 100:580–584.
doi:10.1186/1477-7819-12-298
Cite this article as: Portolani et al.: Parietal and peritoneal localizations
of hepatocellular carcinoma: is there a place for a curative surgery?
World Journal of Surgical Oncology 2014 12:298.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
